Core Insights - The 32nd Shenzhen International Tea Expo has commenced, showcasing the high-quality development of the Chinese tea industry through various themed events and exhibitions [1][3] - The expo features an exhibition area of 75,000 square meters with 3,700 booths, gathering over 2,000 brand enterprises from home and abroad [3] - The event highlights the vibrant tea consumption market in the Greater Bay Area, with numerous well-known brands participating and engaging in discussions and collaborations [3][7] Group 1 - The expo includes various concurrent events such as the "2025 Chaozhou Kung Fu Tea Conference" and the "World Aged Tea Awards," enhancing the overall experience for attendees [1] - A diverse range of tea products and cultural exchanges are present, attracting thousands of professional buyers and tea enthusiasts [3][7] - The event aims to break traditional exhibition formats by incorporating multi-dimensional content to enhance tea culture experiences [7] Group 2 - The 2025 Shenzhen International Tea Ware Aesthetic Design Exhibition features various themed areas, showcasing both traditional craftsmanship and contemporary design [5] - Notable brands and products, including limited edition items and innovative designs, are highlighted, emphasizing the creativity within the tea ware sector [5] - The international section of the expo has expanded, attracting tea enterprises and cultural institutions from regions such as Hong Kong, Macau, Taiwan, and countries like Malaysia and Japan [7]

Core Viewpoint - The 2025 Shenzhen International High-Performance Medical Device and Innovative Pharmaceutical Exhibition aims to create an industry exchange platform, focusing on the theme of "Innovative Drugs and Devices, Collaborative Win-Win" to showcase cutting-edge achievements in the pharmaceutical and medical device industries and promote cooperation between Shenzhen and Hong Kong [1] Group 1: Exhibition Overview - The exhibition will take place in Hong Kong on December 11 and in Shenzhen from December 18 to 20, featuring a dual-city model [1] - The Hong Kong segment will focus on international clinical trials, technology and product exports, cell and gene therapy, AI in medical devices, and brain science [1] - The Shenzhen segment will cover the entire pharmaceutical and medical device supply chain, showcasing high-performance medical devices and innovative pharmaceuticals, including biomanufacturing, AI+healthcare, aesthetic devices, and home health [1] Group 2: Participation and Forums - The exhibition will feature over 300 participating companies and institutions, including global leaders like Siemens Healthineers, Medtronic, and Abbott, as well as domestic pioneers [2] - More than 20 high-level sub-forums will be held, addressing key topics such as policy interpretation, cutting-edge technology, clinical practice, market trends, and investment financing [2] - Notable experts and over 2,500 industry leaders will attend the opening ceremony and forums to share insights [2] Group 3: Highlights and Achievements - The exhibition will showcase five major highlights: high standards, broad fields, complete supply chains, new achievements, and a comprehensive ecosystem [3] - Significant technological advancements in Shenzhen's pharmaceutical and medical device sectors will be announced during the opening ceremony [3] - Shenzhen's medical device industry has been integrated into the "20+8" key industrial clusters, with a projected growth in output value from 128 billion to 157.6 billion yuan from 2020 to 2024, maintaining an annual growth rate of 5.3% [3]

Core Viewpoint - The 2025 Shenzhen International High-Performance Medical Device and Innovative Pharmaceutical Exhibition will take place in two phases, with the Hong Kong station starting on December 11 and the main exhibition in Shenzhen from December 18 to 20, showcasing advancements in the medical device and pharmaceutical industries [1][2]. Group 1: Exhibition Overview - The exhibition adopts a "one exhibition, two cities" model, focusing on the latest achievements from innovation to industrial transformation, and aims to create a platform for industry exchange, resource integration, and trade [2][3]. - The Hong Kong station will emphasize international clinical trials, technology and product exports, and new fields such as AI in medical devices and brain science, while the Shenzhen station will cover the entire pharmaceutical and medical device supply chain [2][3]. Group 2: Industry Development - Shenzhen's pharmaceutical and medical device output is projected to grow from 128 billion yuan in 2020 to 157.6 billion yuan by 2024, with an annual growth rate of 5.3%, maintaining its position as the national leader in medical device output [3]. - The city plans to establish a development framework consisting of "one corridor, two zones, and three bases" to enhance its biopharmaceutical and medical device industries [3]. Group 3: Regional Focus - Pingshan District, as a national biopharmaceutical industry base, has established 13 specialized parks covering over 2.79 million square meters, with a compound annual growth rate of 39.8% in enterprise numbers [4]. - The Guangming District has attracted over 900 medical device companies and is focusing on building a comprehensive ecosystem for biomanufacturing and innovative medical devices [5][6]. Group 4: Exhibition Highlights - The exhibition will feature over 300 participating companies, including international giants like Siemens and Medtronic, and will host more than 20 sub-forums covering key topics such as policy interpretation and cutting-edge technologies [7][8]. - This year's exhibition will continue to emphasize the dual focus on pharmaceuticals and medical devices, showcasing a wide range of innovations and establishing a complete industry chain from research to application [7][8].

Core Points - Shenzhen Airport has successfully launched a direct flight route to Tawau, Malaysia, marking the 60th international passenger route and restoring the airport's international and regional passenger route count to historical peak levels [1] - The airport has opened and enhanced 27 international passenger routes this year, connecting to 60 cities across five continents, with plans to launch a direct flight to Melbourne, Australia [1] - The number of inbound and outbound passengers at Shenzhen Airport has exceeded 6 million in the first 11 months of the year, a 23.4% year-on-year increase, with foreign passenger numbers rising by 44% and visa-free foreign arrivals increasing by 131.8% [1] Industry Developments - With the official operation of the third runway, Shenzhen Airport's annual passenger capacity is expected to reach 80 million, supporting the city's efforts to enhance its global influence and contribute to the construction of a world-class airport cluster in the Guangdong-Hong Kong-Macao Greater Bay Area [2] - The airport aims to improve hardware facilities, optimize personnel inspection processes, implement customs policies, and provide efficient services to elevate its role as an aviation hub and support high-level opening and high-quality development [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 本月底法定/註冊股本總額： HKD 3,000,000,000 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 公司名稱: 深圳國際控股有限公司 呈交日期: 2025年12月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00152 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 3,000,000,000 | HKD | | 1 | HKD | | 3,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | ...

Core Viewpoint - Shenzhen International (00152) announced the appointment of Ms. Liu Xiuli as the Executive Director and Chief Financial Officer, effective from November 28, 2025 [1] Company Summary - Ms. Liu Xiuli will assume the roles of Executive Director and Chief Financial Officer at Shenzhen International [1]

Group 1 - Shenzhen International (00152.HK) announced the appointment of Liu Xiuli as the executive director and chief financial officer, effective from November 28, 2025 [1]

（於百慕達註冊成立之有限公司） （股份代號：00152） 董事名單與角色和職能 自 2025 年 11 月 28 日起，深圳國際控股有限公司董事會（「董事 會」）成員載列如下： 執行董事 李海濤 （主席） 劉征宇 （總裁） 王沛航 劉秀麗 非執行董事 蔡曉平 獨立非執行董事 潘朝金 曾 志 王國文 丁春艷 各董事會成員於董事會轄下委員會中所擔任的職位載列如下： | | | | | | | | | | | | 董事委員會 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 成員 | 主席 | 成員 | | | | | | | 委員會 | 審核 | | 成員 | | | 主席 | | | 成員 | | | | 委員會 | 提名 | | | 成員 | | 主席 | 成員 | | | | | | 委員會 | 薪酬與考核 | | 丁春艷 成員 | 王國文 | 曾 志 成員 | 潘朝金 | 蔡曉平 | 劉秀麗 | 王沛航 成員 | 劉征宇 主席 | 李海濤 | 董事 | 委員會 | 可持續發展 | 2025 年 1 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 劉 女 士 已 與 本 公 司 訂 立 董 事 服 務 合 同 ， 自 2025年 11月 28日起計為期 3 年，惟其需根據本公司的《組織章程大綱及公司細則》於本公司下屆 股東週年大會上退任並膺選連任。根據與 劉 女士訂立的服務合同， 劉 女 士 的 董 事 酬 金 由 每 年 的 基 本 薪 酬 人 民 幣 500,000元 及 酌 情 花 紅 構 成 （董事會將會每年檢討）， 此乃董事會根據本公司之薪酬與考核委員 會之建議，經考慮其經驗及於本公司之職責後釐定。 除上文所披露者外，於本公告日期， 劉 女士並無於本集團擔任或曾擔 任 任 何 職 位 及 於 過 往 3年 並 無 於 其 他 上 市 公 司 擔 任 或 曾 擔 任 任 何 董 事 職務，概無與本公司之任何董事、高級管理人員、主要股東及 ╱或控 股股東（定義見香港聯 合交易所有限公司證券上市規則（「上市規則 」）） 有任何關係。 （ 於 ...

1、 組織架構 1.1 提名委員會（「委員會」）是深圳國際控股有限公司（「本公司」）董事 會（「董事會」）轄下的委員會，由董事會授權代其履行載於下文職權 範圍的事宜。 深圳國際控股有限公司 董事會提名委員會 職權範圍書 2、 組成 3、 委員會主席 3.1 委員會主席必須為本公司董事會主席或獨立非執行董事，由委員互選 後再經董事會委任。所有會議應由委員會主席主持，若委員會主席缺 席任何會議，出席會議之委員可以推選另一名委員主持該委員會會 議。 3.2 委員會主席應出席股東週年大會回答股東有關委員會事務的諮詢。 4、 匯報程序及會議次數 - 1/4 - 2.1 委員會須由最少三位委員組成，其中獨立非執行董事應當佔多數，且 至少一位委員為不同性別。 2.2 委員會委員均由董事會經考慮委員會的建議後委任、更替及罷免。 2.3 僅委員會委員有權出席會議，但委員會可在適當情況下邀請其他董事 會成員、高級管理人員或其他部門代表出席會議。外聘顧問亦可被邀 請出席委員會會議。 4.1 委員會秘書由委員會委任、更替及罷免，原則上由人力資源部部門負 責人擔任。 4.2 任何委員可透過委員會秘書召開委員會會議。委員會每年應召開最少 ...